At a glance
ClinicalIndex Comparison Record- ✓Age 18-75 years
- ✓Diagnosis of trigeminal neuralgia confirmed by IHS criteria
- ✓On stable dose of concomitant TN medications for at least 4 weeks before randomization
- ✓If currently on tricyclic antidepressant, anticonvulsant, or Class I antiarrhythmic, must maintain stable doses throughout study
- ✕Serious hepatic, respiratory, hematologic, cardiovascular, or renal condition
- ✕Neurologic pain other than TN (except occasional migrainous/tension-type headaches <4 per month)
- ✕Opioid analgesic use >2 days per week for neuralgia treatment
- ✕Concurrent use of sodium valproate
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind Placebo Controlled Add-on Study to Determine the Efficacy and Safety of Lamictal (Lamotrigine) in Patients With Trigeminal Neuralgia (Tic Doloureux)
In Brief
A clinical study evaluating lamotrigine and Placebo for Trigeminal Neuralgia. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This research study will look at the safety (e.g., the occurrence of side effects) and efficacy (how well the drug works in reducing trigeminal neuralgia attacks) of a drug called lamotrigine in adults with trigeminal neuralgia.
Study Details
Timeline
Interventions
The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.